MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...